Internal medicine, Surgery, Oncology, Melanoma and Cancer are her primary areas of study. Katherine S. Panageas combines subjects such as Gastroenterology and Pathology with her study of Internal medicine. She interconnects Clinical trial and Epidemiology in the investigation of issues within Surgery.
The Oncology study combines topics in areas such as Tolerability, Cumulative incidence, Retrospective cohort study and Lung. Her studies deal with areas such as Immune system, Immunology, Ipilimumab and Family history as well as Melanoma. Her Cancer study combines topics from a wide range of disciplines, such as Disease, Soft tissue, Myocardial infarction, Thrombosis and Median survival.
Katherine S. Panageas focuses on Internal medicine, Oncology, Melanoma, Surgery and Cancer. Her work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Pathology. Her biological study spans a wide range of topics, including Proportional hazards model, Disease, Retrospective cohort study and Phases of clinical research.
Katherine S. Panageas has included themes like Immunology, Immune system and Immunotherapy in her Melanoma study. Her Immune system research is multidisciplinary, relying on both Cytotoxic T cell, Antibody and Antigen. Her Cancer research is multidisciplinary, incorporating perspectives in Epidemiology and Cohort.
Her primary scientific interests are in Internal medicine, Oncology, Melanoma, Cancer and Cancer research. Her Internal medicine study typically links adjacent topics like Gastroenterology. Her work in the fields of Oncology, such as Progression-free survival, overlaps with other areas such as Perifosine.
Her Melanoma study combines topics in areas such as Nivolumab, Ipilimumab, Immunotherapy and Long term outcomes. Katherine S. Panageas has researched Cancer in several fields, including Odds ratio, Epidemiology and Emergency medicine. Her Cancer research research is multidisciplinary, incorporating elements of Immune checkpoint, T cell, CD8, Immune system and Kinase.
Her primary areas of investigation include Internal medicine, Oncology, Melanoma, In patient and Clinical trial. Her study connects Gastroenterology and Internal medicine. Her research in Oncology intersects with topics in Glioblastoma, Neurology, Chemotherapy and EGFR Amplification.
Her Melanoma research includes elements of Stage, Nivolumab, Ipilimumab and Cohort. Her study in Clinical trial is interdisciplinary in nature, drawing from both Methotrexate, Ibrutinib, Refractory and Rituximab. Her Cancer research incorporates elements of Odds ratio, Absolute risk reduction, Epidemiology, Myocardial infarction and Diagnosis code.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
How To Build and Interpret a Nomogram for Cancer Prognosis
Alexia Iasonos;Deborah Schrag;Ganesh V. Raj;Katherine S. Panageas.
Journal of Clinical Oncology (2008)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat;Nelly G. Adel;Thu-Oanh Dang;Parisa Momtaz.
Journal of Clinical Oncology (2015)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang;Michael A. Postow;Michael A. Postow;Robert J. Orlowski;Rosemarie Mick.
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival
Geoffrey Y. Ku;Jianda Yuan;David B. Page;Sebastian E. A. Schroeder.
The effect of clustering of outcomes on the association of procedure volume and surgical outcomes.
Katherine S. Panageas;Deborah Schrag;Elyn Riedel;Peter B. Bach.
Annals of Internal Medicine (2003)
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
Jae H. Park;Baozhen Qiao;Katherine S. Panageas;Maria J. Schymura.
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Jianda Yuan;Matthew Adamow;Brian A. Ginsberg;Teresa S. Rasalan.
Proceedings of the National Academy of Sciences of the United States of America (2011)
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial
Richard D. Carvajal;Richard D. Carvajal;Jeffrey A. Sosman;Jorge Fernando Quevedo;Mohammed M. Milhem.
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection.
Deborah Schrag;Katherine S. Panageas;Elyn Riedel;Lillian Hsieh.
Journal of Surgical Oncology (2003)
Tumor-Infiltrating Lymphocytes Predict Sentinel Lymph Node Positivity in Patients With Cutaneous Melanoma
Rebecca C. Taylor;Ami Patel;Katherine S. Panageas;Klaus J. Busam.
Journal of Clinical Oncology (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: